# NovoCure Limited (NVCR) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $13.43, market value $1.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). NovoCure Limited reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 4.3×**. The shares trade at 4.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -1.6%** (5-yr avg -2.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 77.0%**. NovoCure Limited keeps 77.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -17.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -20.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -40.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -22.3%**. Return on all capital, debt included, is -22.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.1%**. Each dollar of assets produces -15.1% of profit.

## Growth
- **Revenue growth (1 yr): 8.3%** (3-yr 6.8%/yr, 5-yr 5.8%/yr). Revenue grew 8.3% over the last year, against 5.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 21.8%**. Earnings per share rose 21.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.57**. Debt is 0.57 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. NovoCure Limited holds more cash than debt.
- **Current ratio: 2.90** (quick 2.90). Current assets cover the next year's liabilities 2.90 times.
- **Altman Z-score: 3.44**. A Z-score of 3.44 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. NovoCure Limited does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover NovoCure Limited; the consensus is buy, with an average price target of $26.43 (+97% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 3.1%** (YTD 2.2%, 3-mo -13.8%). The shares are up 3.1% over twelve months including dividends.
- **From 52-week high: -37.4%** (36.8% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 35**. An RSI of 35 is neutral.
- **Beta (1 yr): 1.55** (volatility 80%). Beta of 1.55 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NVCR · Page: https://foliofundamentals.com/stocks/nvcr

Not investment advice.